Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 295

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 295
---
 when payment is made, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) ASC 730, Research and Development. Research and Development expense was $548,486 for the nine months ended February 28, 2025, compared to $873,746 for the nine months ended February 29, 2024. The decrease reflects a decrease of approximately $138,000 in stock based compensation expense, lower personnel costs from salary reductions and reduced, and other direct expenses for our CogniMIR ®product candidate corresponding to the decrease in available grant funding. Decreased stock -basedcompensation primarily reflects greater vesting of options to DiamiR’s CEO in the nine months ended February 28,

170

2025. Certain other options and RSUs awarded to DiamiR’s CEO vest upon the achievement of specified financing and development milestones not currently considered probable, for which significant stock -basedcompensation expense may be recognized in future periods. General and Administrative Expenses General and administrative expenses consist primarily of professional fees for legal, consulting, auditing, and tax services, patent costs and personnel costs, including stock -basedcompensation. Other general and administrative expenses include facility and office expenses, conference fees and travel. General and Administrative expense was $503,517 for the nine months ended February 28, 2025 compared to $456,314 for the nine months ended February 29, 2024. In the nine months ended February 28, 2025, DiamiR expensed approximately $140,000 of deferred offering costs, which was partially offset by decreased employee compensation and consulting fees in the period. Interest Expense Interest expense relates to interest accrued and the amortization of discounts on loans obtained from founders. Interest expense was $59,451 for the nine months ended February 28, 2025 compared to $33,473 for the nine months ended February 29, 2024, The increase reflects additional loans received from the founders in the intervening periods. Income Taxes Income Tax expense was $14,346 and $82,383 for the nine months ended February 28, 2025 and February 29, 2024, respectively, and reflects a provision for uncertain tax positions related to research and development expenses and is subject to changes in periodic revenue and expense levels. Lower income tax expense for the nine months ended February 28, 2025 reflects the impact of lower grant revenue in the period. Years Ended May 31, 2024 and 2023